3
Clinical antifungal resistance in fungi has been best characterized with azole drugs and is associated with a variety of mechanisms including direct modification of the target enzyme, levels of the target enzyme, decreased drug accumulation due to efflux pump overexpression, or some combination of these mechanisms (14) . Less is known about echinocandin reduced susceptibility, but resistance in Candida spp. has been associated only with mutations in the Fks1p subunit of the target enzyme (1,3)-ß-Dglucan synthase (4-6, 9). Hakki et al recently reported a case of invasive and oropharyngeal candidiasis caused by a C. krusei isolate that developed reduced echinocandin susceptibility (RES) after caspofungin (CFG) therapy, The preliminary evaluation did not reveal any modification of FKS1 gene sequence in the isolate with reduced susceptibility (2) . To determine if the RES phenotype in this strain could be due to a different mechanism, pre-and post-CFG treatment strains were further assessed for genetic and biochemical modifications of glucan synthase.
Echinocandin susceptibility testing with CFG, micafungin (MFG) and anidulafungin (ANG) was performed in triplicate using the broth microdilution method of the CLSI document M27-A2 (15) with modifications (9). C. krusei strains (2) Ck98 (pretreament) and Ck100 (post-treatment) were grown with vigorous shaking at 30°C to early stationary phase in YPD broth (Yeast extract 2%, BactoPeptone 4%, Dextrose 4%). GS isolation and CFG titration were done as described previously (9). Inhibition curves and Strain Ck-100 showed a 16-32 fold increase in MIC values for echinocandin drugs relative to the pre-treatment susceptible strain, Ck-98 (Table 1) , as previously reported (2) . Moreover, the Ck-100 CFG MIC value exceeded the maximum range of 1 µg/ml reported for several large collections of clinical isolates using the CLSI M-27-A2 method (8, 10-13). The reduced microbiological susceptibility of Ck-100 to CFG was confirmed in glucan synthase enzyme assays. A standard monophasic inhibition curve was obtained for Ck-98 yielding an IC 50 of 6.8 ng/ml (Figure 1 ). In contrast, biphasic inhibition was obtained for product-entrapped enzyme from the Ck-100 strain, with IC 50 values of 8.4 ng/ml and 3942 ng/ml (Fig. 1) . The presence of two distinct inflection GenBank accession no. D88815). Both wild-type and the G substituted fks1 gene were observed in each of the five PCR products analyzed from strain Ck-100 (Fig. 2C, D) .
This nucleotide heterozygosity results in deduced amino acid heterogeneity -the wild type TTC codon encoding F, and the modified TGC codon encoding C (Fig. 2B) . None of the PCR products amplified from Ck-98 genomic DNA shared this nucleotide substitution ( Fig. 2A) . Failure to detect mutations in FKS1 previously (2) likely results from the analysis of only one cloned allele. Since C. krusei is a diploid or aneuploid organism (3, 17) , the cloning of one allele or other in a bacterial plasmid is a matter of chance.
The amino acid substitution at this position in C. krusei Fks1p is located in the highly conserved "Hot Spot 1" region of the protein (Fig. 2B) (9) . Heterozygous amino acid changes in this region are associated with CFG resistance in both S. cerevisiae laboratory strains and C. albicans clinical isolates (5, 6, 9). However, the only other reported C. krusei clinical isolate with RES had a predicted R1361G substitution in "Hot Spot 2" of Fks1p (9). Thus, the Ck-100 clinical isolate is the first echinocandin resistant C. krusei strain to be associated with a mutation in "Hot Spot 1."
The results obtained in this work highlight the need to monitor C. krusei infections treated with echinocandin drugs for the development of resistance. This is especially important because mortality from C. krusei, like other Candida spp., remains high (7, 16, 18) and treatment options are limited due to intrinsic resistance to fluconazole (1). 
A C C E P T E D

